“The existing problem has exposed some structural weaknesses while in the EU’s medicines offer chain and also a higher dependence on non-EU international locations for active pharmaceutical ingredients,” Kyriakides said. She advised that supply chain concerns be dealt with in an EU pharmaceutical method predicted to be launched by the end fro